Blueprints of Life: Unlocking the Power of Modern Biotechnology
Articles

HYPERTENSION MANAGEMENT: TACKLING THE CLINICAL CHALLENGES OF OMAPATRILAT AND ITS ANALOGUES (SAMPATRILAT AND SAMASP) IN HYPERTENSION THERAPY

PDF
  • Ananyo Mazumdar,
  • Aditya Das,
  • Beas Dutta,
  • Tiyasa Manna,
  • Priyajit Banerjee
Ananyo Mazumdar
Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, 700121, West Bengal, India.
Aditya Das
Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, 700121, West Bengal, India.
Beas Dutta
Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, 700121, West Bengal, India.
Tiyasa Manna
Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, 700121, West Bengal, India.
Priyajit Banerjee
Corresponding Author. Dr. Priyajit Banerjee, Assistant Professor, Department of Biotechnology, School of Life Sciences, Swami Vivekananda University, Barrackpore, West Bengal- 700121

Published 2025-12-03

Keywords

  • Vasopeptidase,
  • hypertension,
  • Omapatrilat,
  • Sampatrilat,
  • off-target,
  • angiodema
    • ...More
    Less

How to Cite

Mazumdar, Ananyo, et al. “HYPERTENSION MANAGEMENT: TACKLING THE CLINICAL CHALLENGES OF OMAPATRILAT AND ITS ANALOGUES (SAMPATRILAT AND SAMASP) IN HYPERTENSION THERAPY”. Swami Vivekananda University Press, Dec. 2025, pp. 225-37, https://swamivivekanandauniversitypress.com/index.php/svup/article/view/181.

Copyright (c) 2025 Swami Vivekananda University Press

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Abstract

Vasopeptidase inhibitors have shown great efficacy in treating hypertension patients over decades. VPIs like omapatrilat effectively target both neprilysin (NEP) and angiotensin-converting enzyme (ACE) for blood pressure control but suffer from severe side effects due to off-target activity. Omapatrilat inhibits NEP, nACE, and cACE, but itleads to excessive accumulation of bradykinin and substance P, which contribute to adverse effects such as angiodema. This review explores the dynamics of this drug and its analogue molecules, addressing the issues behind its stop in clinical usage and how adjusting the inhibitor design can reduce the off-target effects,mitigating bradykinin-related side effects.

DOI - https://doi.org/10.65525/SVUP.9788198800473.2025.225-237

PDF